Medical/Pharmaceuticals

Nuance Pharma Announces Clearance of IND Application for Respiratory Syncytial Virus (RSV) Vaccine in China

SHANGHAI, Nov. 13, 2022 /PRNewswire/ -- Nuance Pharma ("the Company") announces the Center for Drug Evaluation ("CDE") has approved its Investigational New Drug ("IND") application supporting its pivotal phase III clinical trial of MVA-BN RSV vaccine against respiratory syncytial virus (RSV) in a...

2022-11-14 09:54 3167

Akeso's Ivonescimab (PD-1/VEGF Bispecific Antibody, AK112) Granted Breakthrough Therapy Designation for I-O Resistance NSCLC Patients in China

* AK112 has now been granted three Breakthrough Therapy Designations for NSCLC * The only drug candidate granted Breakthrough Therapy Designation for I-O Resistance NSCLC inChina HONG KONG, Nov. 13 /PRNewswire/ -- Akeso, Biopharma (9926. HK) ("Akeso") announced that the Center for Drug Evaluati...

2022-11-14 08:00 3497

SK Biopharmaceuticals Receives Korea Drug Development Fund Investment Grant to Develop Novel Oncology Candidate, SKL27969

State-run financing to provide two-year support of Phase 1 research for oncology candidate, SKL27969, for the potential treatment of advanced solid tumors SK Biopharmaceuticals to present preclinical data on oncology candidate, SKL27969, at Society for Neuro-Oncology Conference PANGYO, South Ko...

2022-11-14 08:00 3316

CHOCOLATE TOUCH®, NEXT-GENERATION DRUG-COATED ANGIOPLASTY BALLOON FOR THE TREATMENT OF PERIPHERAL ARTERIAL DISEASE RECEIVES FDA APPROVAL

SINGAPORE, Nov. 11, 2022 /PRNewswire/ -- Genesis MedTech Group announced today that the Food and Drug Administration (FDA) has approved the Chocolate Touch® Drug-coated Balloon PTA Catheter, developed by TriReme Medical LLC, for the treatment of patients with peripheral artery disease in the s...

2022-11-11 14:00 2748

J INTS BIO, Novel Oral 4th Generation EGFR TKI 'JIN-A02' - Phase 1/2 IND approved by US FDA

- First patient expected in December 2022 SEOUL, South Korea, Nov. 10, 2022 /PRNewswire/ -- J INTS BIO announced on November 9th that it had received approval from the US FDA for its Phase 1/2 clinical trial of its Novel Oral 4th Generation EGFR TKI 'JIN-A02' in patients with advanced non-small ...

2022-11-11 10:30 2909

Harbour BioMed Enters into a License and Collaboration Agreement with Moderna

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Nov. 10, 2022 /PRNewswire/ -- Harbour BioMed (the "Company", HKEX: 02142) today announced that Nona Biosciences, a subsidiary wholly owned by the Company, had entered into a license and collaboration agreement with ModernaTX, Inc. (NASDA...

2022-11-11 09:03 3309

Antengene Presents Promising Results from Four Preclinical Studies at the 2022 Society for Immunotherapy of Cancer Annual Meeting

-   Oral presentation highlights preclinical data with ATG-031, an in-house discovered anti-CD24 monoclonal antibody,tracking to an investigational new drug (IND) filing in H1:2023 -   Three poster presentations showcase preclinical data with three programs developed or discovered in-house,ATG-1...

2022-11-11 08:30 3460

Alma Academy was Successfully Held in Dubai with the Global Launch of Alma Duo

HONG KONG, Nov. 10, 2022 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", stock code: 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global consumer wellness group, is pleased to announce that, with over 500 physicians from 47 countries around th...

2022-11-10 23:57 4051

CBC-backed ABio-X appoints pharmaceutical and healthcare veteran Dr. Jeffrey Jonas as CEO

WALTHAM, Mass., Nov. 10, 2022 /PRNewswire/ -- ABio-X, the Massachusetts-based biotech incubation platform focused on transformative medicines and breakthrough technologies, today announced the appointment ofJeffrey Jonas, M.D., as its Chief Executive Officer (CEO). Dr. Jonas brings with him mo...

2022-11-10 21:00 3502

Asieris Obtained IND Approval from US FDA for APL-1401, a New Drug for the Treatment of Moderately-to-Severely Active Ulcerative Colitis

SHANGHAI, Nov. 10, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs, announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) appl...

2022-11-10 19:02 2510

Ascentage Pharma Announces IND Approval in China for Phase I Study of APG-5918 in Patients with Advanced Solid Tumors or Hematologic Malignancies

SUZHOU, China and ROCKVILLE, Md., Nov. 9, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its novel inhibitor of the embryonic ectoderm ...

2022-11-10 11:36 2605

Kintor Pharma Announces Oral Presentation at ASH 2022 Highlighting the Data from Novel Dual c-Myc/GSPT1 Degrader GT19715

SUZHOU, China, Nov. 9, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("KintorPharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the results from the novel dual c-Myc/GSPT1 degrader GT19715 have been s...

2022-11-10 09:12 2963

ALPINION MEDICAL SYSTEMS SHOWCASING THE LATEST INTELLIGENT ULTRASOUND TECHNOLOGY AT RSNA 2022

Unveiling Upgraded Top-Tier 'X-CUBE 90 on GPX' and Debuting Value Console 'X-CUBE 60' Unit Are Among the New-Generation of Diagnostic Ultrasound Systems to Be Demonstrated at the Radiological Society ofNorth America's Annual Medical Exhibition SEOUL, South Korea, Nov. 9, 2022 /PRNewswire/ -- ALP...

2022-11-10 04:50 3686

Axiomtek launches the newest medical grade artificial intelligence computing system - mBOX100

TAIPEI, Nov. 9, 2022 /PRNewswire/ -- Axiomtek – a world-renowned leader relentlessly devoted to the research, development, and manufacturing of innovative and reliable industrial computer products of high efficiency – is pleased to announce the release of themBOX100, a medical-grade edge AI comp...

2022-11-09 17:21 3205

Amorepacific publishes its findings on dietary restrictions and lifespan extension in Nature Communications

* Discovered the effects of the essential amino acid, threonine, on promoting both life and healthspans. * Research findings will be applied to product development of its brand, VITAL BEAUTIE. SEOUL, South Korea, Nov. 8, 2022 /PRNewswire/ -- Amorepacific discovered a mechanism of dietary rest...

2022-11-08 22:00 2876

Traditional Chinese Medicine Lianhua Qingwen Attracted Eyes in the Annual National Conference of Pharmaceutical Society of Nigeria

SHIJIAZHUANG, China, Nov. 8, 2022 /PRNewswire/ -- Recently, the 95th National Annual Conference of the Pharmaceutical Society ofNigeria was held in Jos, capital of Plateau State. The theme of the Conference in this year was "Medicine Security in an Unstable Economy", and more than 3,000 doctors a...

2022-11-08 20:25 2806

111 to Announce Third Quarter 2022 Unaudited Financial Results on December 1, 2022 - Conference Call to Follow

SHANGHAI, Nov. 8, 2022 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced that it will report its unaudited financial results ...

2022-11-08 14:09 2665

Alterity Therapeutics Announces Presentation of Data from the bioMUSE Natural History Study at the American Autonomic Society Annual Meeting

MELBOURNE, Australia and SAN FRANCISCO, Nov. 7, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced a poster presentation fro...

2022-11-07 23:25 3458

National Institute of Korean Medicine shows a new trend in Korean Medicine in Times Square, New York

Korean wave towards K-medicine, from K-food, K-pop and K-movies SEOUL, South Korea, Nov. 7, 2022 /PRNewswire/ -- The National Development Institute of Korean Medicine (NIKOM) said a promotional video showing the value of Korean Medicine will be played on the electronic display of the Nasdaq buil...

2022-11-07 23:00 2740

SeekIn Demonstrates the Power of Treatment Response Monitoring Test at the Association for Molecular Pathology (AMP) 2022 Annual Meeting & Expo

SeekInClarity is a CE-IVD Mark, cost-effective, blood-based pan-cancer/pan-indication treatment response monitoring test that does not require cancer tissue analysis. SeekInClarity test could identify a subgroup of patients as responders, who have better survival regardless of disease subtypes a...

2022-11-07 21:00 2169
1 ... 208209210211212213214 ... 263

Week's Top Stories